Q3 EPS Estimate for Ultragenyx Pharmaceutical Cut by Analyst

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at William Blair reduced their Q3 2025 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a report issued on Tuesday, August 5th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will post earnings of ($1.34) per share for the quarter, down from their prior forecast of ($1.32). William Blair currently has a “Outperform” rating and a $65.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. William Blair also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at $0.42 EPS and FY2026 earnings at ($1.06) EPS.

Other equities analysts have also recently issued research reports about the company. HC Wainwright raised Ultragenyx Pharmaceutical to a “buy” rating and set a $80.00 price target for the company in a report on Monday, July 28th. Canaccord Genuity Group cut their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a report on Friday. Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Guggenheim reaffirmed a “buy” rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Finally, Wedbush cut their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a report on Monday, July 14th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $81.50.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $27.54 on Friday. The stock has a 50-day simple moving average of $33.32 and a 200 day simple moving average of $36.78. The stock has a market capitalization of $2.65 billion, a PE ratio of -4.98 and a beta of 0.25. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The business had revenue of $166.50 million during the quarter, compared to analysts’ expectations of $161.37 million. During the same quarter in the previous year, the firm earned ($1.52) EPS. The firm’s revenue was up 13.2% compared to the same quarter last year.

Insider Buying and Selling

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the sale, the director directly owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System grew its position in Ultragenyx Pharmaceutical by 0.3% during the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock worth $3,284,000 after acquiring an additional 268 shares during the last quarter. GAMMA Investing LLC grew its position in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 323 shares during the last quarter. Xponance Inc. grew its position in Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company’s stock worth $455,000 after acquiring an additional 347 shares during the last quarter. BOKF NA boosted its position in Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 382 shares during the last quarter. Finally, Oak Ridge Investments LLC boosted its position in Ultragenyx Pharmaceutical by 2.3% in the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company’s stock valued at $643,000 after buying an additional 395 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.